OncoSil Medical (ASX:OSL) FCF Margin % : -1,334.64% (As of Dec. 2024)

View and export this data going back to 2005. Start your Free Trial

What is OncoSil Medical FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. OncoSil Medical's Free Cash Flow for the six months ended in Dec. 2024 was A$-6.13 Mil. OncoSil Medical's Revenue for the six months ended in Dec. 2024 was A$0.46 Mil. Therefore, OncoSil Medical's FCF Margin % for the quarter that ended in Dec. 2024 was -1,334.64%.

As of today, OncoSil Medical's current FCF Yield % is -70.26%.

The historical rank and industry rank for OncoSil Medical's FCF Margin % or its related term are showing as below:

ASX:OSL' s FCF Margin % Range Over the Past 10 Years
Min: -4360.34 Med: -3627.31 Max: -1457.88
Current: -1457.88

During the past 13 years, the highest FCF Margin % of OncoSil Medical was -1457.88%. The lowest was -4360.34%. And the median was -3627.31%.

ASX:OSL's FCF Margin % is ranked worse than
94.9% of 823 companies
in the Medical Devices & Instruments industry
Industry Median: -3.62 vs ASX:OSL: -1457.88

OncoSil Medical FCF Margin % Historical Data

The historical data trend for OncoSil Medical's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OncoSil Medical FCF Margin % Chart

OncoSil Medical Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

FCF Margin %

Get a 7-Day Free Trial

-4,163.85

-4,360.34

-3,090.76

-2,152.22

OncoSil Medical Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
FCF Margin %	Get a 7-Day Free Trial															-2,503.70	-3,950.33	-4,894.32	-1,589.74	-1,334.64

Competitive Comparison of OncoSil Medical's FCF Margin %

For the Medical Devices subindustry, OncoSil Medical's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

OncoSil Medical's FCF Margin % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, OncoSil Medical's FCF Margin % distribution charts can be found below:

* The bar in red indicates where OncoSil Medical's FCF Margin % falls into.

Save Embed

;

Save Embed

;

OncoSil Medical FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

OncoSil Medical's FCF Margin for the fiscal year that ended in Jun. 2024 is calculated as

FCF Margin	=	Free Cash Flow (A: Jun. 2024 )	/	Revenue (A: Jun. 2024 )
	=	-11.127	/	0.517
	=	-2,152.22 %

OncoSil Medical's FCF Margin for the quarter that ended in Dec. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2024 )	/	Revenue (Q: Dec. 2024 )
	=	-6.126	/	0.459
	=	-1,334.64 %

OncoSil Medical FCF Margin % Related Terms

Thank you for viewing the detailed overview of OncoSil Medical's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

OncoSil Medical Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » OncoSil Medical Ltd (ASX:OSL) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

7 Eden Park Drive, Level 5, Macquarie Park, Sydney, NSW, AUS, 2113

Website

https://www.oncosil.com

OncoSil Medical Ltd is a medical device company. It is engaged in the development and commercialization of its product candidate, the OncoSil localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma. It operates in one segment. the device development for new medical treatments. Geographically, the company derives its maximum revenue from Europe and the rest from Australia and New Zealand.

OncoSil Medical Headlines

No Headlines